Secukinumab (cubana) is a recombinant, high-affinity, fully human monoclonal antibody immunoglobulin G1κ selectively binds and neutralizes That interleukin-17A. To confirm the findings of basic research and early clinical studies Regarding the crucial role of interleukin-17A in psoriasis, we Conducted two randomized, phase trials to ASSESS the efficacy and safety of secukinumab, at a dose of 300 mg or 150 mg, administered as induction therapy (with assessment at week 12) and maintenance therapy (with assessment at week 52) in Patients With moderate-to-severe plaque psoriasis. (Efficacy of Response and Safety of Two Fixed Secukinumab regimens in Psoriasis) study secukinumab Compared With placebo, and the ( Examination of Secukinumab vs. Etanercept Using Two Dosing regimens to Determine Efficacy in Psoriasis) study secukinumab Compared With Placebo and, the tumor necrosis factor first (TNF) inhibitor approved by the for moderate-to-severe plaque psoriasis
Alzheimer's disease (AD) has become a growing problem in the medical, psychiatric, neurological, epidemiological, social and economic order, particularly in countries with a high life expectancy Alzheimer's dementia can be classified according to the age of onset in presenile or early onset, which appears before age 65 and senile or late onset, ie onset after age 65. It according to the presence or absence of a family history of the disease is classified into familial AD and sporadic AD, respectively. However, these classifications are not mutually exclusive. The development achieved by genetic has demonstrated the involvement of several chromosomes in the development of the disease. Chromosomes 1, 14 and 21 are associated with familial forms of start precoz. While late onset forms appear linked to chromosomes 12 and 19 In this paper we delved into the study of chromosome 21 and the amyloid beta protein , because there are many findings that relate to deposit excess am...
Comentarios